Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Anish Thomas

Interventional Cardiology Saint Louis, MO Medical Doctor

NPI 1912096231 CMS profile 86231

10012 Kennerly Rd Ste 300, Saint Louis, MO 63128

Open in the dashboard

General payments

$170,515

765 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$150,000

3 holdings reported · through program year 2025

Research they led as principal investigator

$1,264,779 paid to institutions, not to them · program years 2021–2025

Through program year 2025, Anish Thomas of Saint Louis, MO is reported in the CMS Open Payments database as having received $170,515 across 765 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $1,264,779 in research payments, paid to institutions rather than to them. They also declared ownership or investment interests valued at $150,000 across 3 holdings.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 95th percentile of Interventional Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

10 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $10,242 76
2024 General $26,306 129
2023 General $29,322 132
2022 General $21,440 117
2021 General $29,734 101
2020 General $25,132 69
2019 General $28,338 141
2025 Ownership $50,000 1
2024 Ownership $50,000 1
2023 Ownership $50,000 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Anish Thomas
  • Interventional Cardiology median
  • Middle half of Interventional Cardiology
  • National median

In program year 2025, general payments to Anish Thomas were reported at $10,242. Among 6,173 Interventional Cardiology profiles paid that year, the median was $1,092 and the middle half received between $366 and $3,019.

Show as a table
Year Anish Thomas Interventional Cardiology median Middle half National median
2019 $28,338 $1,097 $329–$3,048 $163
2020 $25,132 $473 $161–$1,480 $114
2021 $29,734 $677 $233–$1,827 $132
2022 $21,440 $978 $333–$2,724 $149
2023 $29,322 $1,136 $382–$2,986 $160
2024 $26,306 $1,181 $395–$3,326 $164
2025 $10,242 $1,092 $366–$3,019 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Janssen Pharmaceuticals, Inc $51,015 66 payments
  2. Abbott Laboratories $40,452 123 payments
  3. Terumo Medical Corporation $13,246 23 payments
  4. Shockwave Medical, Inc $11,526 75 payments
  5. Edwards Lifesciences Corporation $11,295 270 payments
  6. Bard Peripheral Vascular, Inc. $9,910 11 payments
  7. Philips Electronics North America Corporation $8,518 46 payments
  8. Medtronic, Inc. $7,786 31 payments
  9. Cardiovascular Systems Inc. $6,658 14 payments
  10. Penumbra, Inc. $2,855 6 payments
  11. Other $7,253 100 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $57,355 32 payments
  2. Consulting Fee $29,879 31 payments
  3. Food and Beverage $25,943 649 payments
  4. Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program $23,000 10 payments
  5. Compensation for serving as faculty or as a speaker for a medical education program $16,888 7 payments
  6. Travel and Lodging $16,547 31 payments
  7. Honoraria $750 1 payment
  8. Education $154 4 payments
Products named General payments · program years 2019–2025
  1. XARELTO $51,066 67 payments
  2. Omnilink Elite vascular stent system $20,457 12 payments
  3. Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter $10,591 61 payments
  4. NAVICROSS $8,175 8 payments
  5. Diamondback Peripheral $6,607 11 payments
  6. Abre $5,444 4 payments
  7. Supera peripheral stent system $5,232 29 payments
  8. GLIDEWIRE $4,773 7 payments
  9. R2P MISAGO $4,048 6 payments
  10. XIENCE SIERRA $4,000 4 payments
  11. Other $50,794 400 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 32 drugs

Part D claims

3,742

Median for Interventional Cardiology: 2,236

Drug cost

$767,176

Median for Interventional Cardiology: $380,412

Branded share of claims

36.3%

Median for Interventional Cardiology: 27.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xarelto Rivaroxaban Brand 216 $231,082
Eliquis Apixaban Brand 192 $200,304
Entresto Sacubitril/Valsartan Brand 134 $139,329
Jardiance Empagliflozin Brand 83 $92,574
Repatha Sureclick Evolocumab Brand 56 $64,676
Prasugrel Hcl Generic 54 $5,937
Clopidogrel Clopidogrel Bisulfate Brand 462 $5,433
Atorvastatin Calcium Generic 474 $5,214
Metoprolol Succinate Generic 347 $3,272
Cilostazol Generic 92 $2,367

The 10 drugs with the highest cost, of 32 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 4,694 Part D prescribers listed as Interventional Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 92 billing codes

Paid by Medicare

$129,417

Medicare's payments for the services billed

Medicare patients

774

Average age 76

Services billed

1,515

386 women, 388 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 64%
Arthritis 52%
Chronic kidney disease 44%
Diabetes 43%
Heart failure 43%
Atrial fibrillation 41%
Depression 31%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 7 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
XARELTO
  • Janssen Pharmaceuticals, Inc $1,030
$1,030 216 —
MULTAQ
  • SANOFI-AVENTIS U.S. LLC $40
$40 — —
Arcalyst
  • Kiniksa Pharmaceuticals International, plc $16
$16 — —
VERQUVO
  • Merck Sharp & Dohme Corporation $16
$16 — —
ELIQUIS
  • PFIZER INC. $13
$13 192 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 7 in the dashboard with a free account

Records

765 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Cardiology in Missouri

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record